1. Screening for Colon Cancer and Evaluation of Chemoprevention with Coxibs 
Douglas K Rex, MD, FACG 
Journal of Pain and Symptom Management 
Volume 23, Issue 4, Pages S41-S50 (April 2002)
DOI: /S (02)

2. Fig. 1
Mechanism of action of aspirin, other nonsteroidal anti-inflammatory drugs, and selective cyclooxygenase-2 (COX-2) inhibitors (Reproduced from Ref. 25, with permission). NF-κB = nuclear factor-κB; PPARδ = peroxisome-proliferator-activated receptor δ.
Journal of Pain and Symptom Management  , S41-S50DOI: ( /S (02) )

3. Fig. 2
Inhibition of polyp size by rofecoxib or sulindac treatment of ApcΔ716 mice (Reproduced from Ref. 60, with permission). Rofecoxib A= % (w/w) = 14.7 mg/kg/day; Rofecoxib B= % (w/w) = 4.7 mg/kg/day; Sulindac = 0.015% (w/w) = 32.6 mg/kg/day.
Journal of Pain and Symptom Management  , S41-S50DOI: ( /S (02) )

4. Fig. 3
Colon carcinogenesis and the effects of chemopreventive agents (Adapted from Ref. 25, with permission). APC = adenomatous polyposis coli gene; COX = cyclooxygenase; coxibs = COX-2-specific inhibitors; NSAIDs = nonsteroidal anti-inflammatory drugs.
Journal of Pain and Symptom Management  , S41-S50DOI: ( /S (02) )

5. Fig. 4
Effects of the cyclooxygenase-2 (COX-2)-specific inhibitor, celecoxib, on colorectal polyps in patients with familial adenomatous polyposis.72 BID = twice daily.
Journal of Pain and Symptom Management  , S41-S50DOI: ( /S (02) )